Headlines about China Cord Blood (NYSE:CO) have trended somewhat positive this week, Accern Sentiment Analysis reports. The research firm rates the sentiment of media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. China Cord Blood earned a media sentiment score of 0.22 on Accern’s scale. Accern also gave press coverage about the medical research company an impact score of 44.5092612488464 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
China Cord Blood (CO) opened at $9.21 on Thursday. The stock has a market capitalization of $1,110.00, a price-to-earnings ratio of 25.58 and a beta of 0.88. China Cord Blood has a 1-year low of $5.06 and a 1-year high of $14.95.
WARNING: This piece was first published by Community Financial News and is owned by of Community Financial News. If you are accessing this piece on another domain, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this piece can be viewed at https://www.com-unik.info/2018/01/11/china-cord-blood-co-earns-coverage-optimism-score-of-0-22.html.
China Cord Blood Corporation is a provider of cord blood banking services in China. The Company and its subsidiaries are principally engaged in the provision of umbilical cord blood storage and ancillary services in the People’s Republic of China. It provides cord blood testing, processing and storage services under the direction of subscribers for a cord blood processing fee and a storage fee.
Receive News & Ratings for China Cord Blood Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Cord Blood and related companies with MarketBeat.com's FREE daily email newsletter.